FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment . . . FDA approved of Regeneron Pharmaceutical’s Libtayo (cemiplimab-rwlc)as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) who are at an increased risk of recurrence following surgery and radiation 1 Libtayo was reviewed by FDA under Priority Review, a method reserved for medicines representing a potential improvement in efficacy or safety in treatments of
FDA Approves Cemiplimab as Adjuvant Treatment for Cutaneous . . . Cemiplimab's approval is supported by findings from the C-POST clinical trial The FDA approved cemiplimab-rwlc (Libtayo; Regeneron Pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) who are at a high risk of recurrence following surgery and radiation
FDA Approves Cemiplimab as Adjuvant Immunotherapy for High . . . Last week, Regeneron announced the U S Food and Drug Administration (FDA) approval of cemiplimab-rwlc (Libtayo) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC), particularly in those with a high risk of recurrence after surgery and radiation 1 The PD-1 inhibitor was evaluated under priority review
FDA Approves Cemiplimab for Adjuvant Cutaneous Squamous Cell . . . The US FDA has approved the supplemental biologics license application (sBLA) for cemiplimab-rwlc (Libtayo) as adjuvant treatment in adults with high-risk cutaneous squamous cell carcinoma (CSCC) 1 The sBLA approval was based on an extensive review of data from the pivotal phase 3 C-POST study (NCT03969004) which demonstrated a statistically significant and clinically meaningful improvement
FDA Approval of Cemiplimab: A New Era for High-Risk CSCC . . . In a significant step forward for skin cancer management, the U S Food and Drug Administration (FDA) has approved cemiplimab-rwlc (Libtayo) as an adjuvant treatment for adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence following surgery and radiation The decision, announced on October 8, 2025, marks the first approval of a PD-1 inhibitor for this specific post
FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCC Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo The Food and Drug Administration (FDA) has approved Libtayo ® (cemiplimab-rwlc) for the
FDA Approves Libtayo to Help Prevent Return of High-Risk Skin . . . The FDA has approved cemiplimab-rwlc (Libtayo) as a new treatment option to help prevent cutaneous squamous cell carcinoma (CSCC) from returning after surgery and radiation This approval brings hope to adults with CSCC who are at high risk of the cancer coming back, offering another way to lower the chances of recurrence Who Can Benefit? This new approval is intended for patients who have